


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula (I):



(I)

wherein:

~~W and Y are independently~~ is a straight or branched chain C<sub>1-5</sub> alkylene group optionally containing one double bond ~~[[,]]~~ or one triple bond ~~or carbonyl~~, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or C<sub>1-4</sub> alkoxy;

Y is a straight or branched chain C<sub>1-5</sub> alkylene group optionally containing one double bond, or one triple bond or carbonyl, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or C<sub>1-4</sub> alkoxy;

X is -NR<sub>3</sub>C(O)-, -C(O)NR<sub>3</sub>, -NR<sub>3</sub>S(O)<sub>2</sub>-, -S(O)<sub>2</sub>NR<sub>3</sub>-,  
-NR<sub>3</sub>C(O)NR<sub>4</sub>-, -NR<sub>3</sub>C(O)O-, -OC(O)NR<sub>3</sub>-, -NR<sub>3</sub>-, ~~C(O)-~~, -CH(OH)-, -C(NH)-, -O-, -S-, -S(O)- or -S(O)<sub>2</sub>-;

R<sub>3</sub> and R<sub>4</sub> are independently H, C<sub>1-4</sub> alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C<sub>1-4</sub> haloalkyl, amino, C<sub>1-4</sub> alkylamino, di-C<sub>1-4</sub>-alkylamino, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> haloalkylthio, C<sub>1-4</sub> haloalkylsulfinyl and C<sub>1-4</sub> haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C<sub>1-4</sub> haloalkyl, amino, C<sub>1-4</sub> alkylamino, di-C<sub>1-4</sub>-alkylamino, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> haloalkylthio, C<sub>1-4</sub> haloalkylsulfinyl and C<sub>1-4</sub> haloalkylsulfonyl;

R<sub>1</sub> is H, ~~hydroxyl~~, halogen, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl;

R<sub>2</sub> is H or C<sub>1-8</sub> alkyl and

"n" and "m" are each independently 0 or 1; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

provided that:

i) ~~when both R<sub>1</sub> and R<sub>2</sub> are H then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>H, C(O)-C<sub>6</sub>H<sub>4</sub>-p-O-C<sub>8</sub>H<sub>17</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OH, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CO<sub>2</sub>H and CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H;~~

ii) ~~when R<sub>1</sub> is CH<sub>3</sub> and R<sub>2</sub> is H then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CH<sub>2</sub>CO<sub>2</sub>H, C(O)CH=CHC<sub>6</sub>H<sub>5</sub>, C(O)C<sub>6</sub>H<sub>4</sub>-p-OCH<sub>3</sub>, CO<sub>2</sub>H, C(O)CH<sub>3</sub>, C(O)C<sub>6</sub>H<sub>4</sub>-o-CH<sub>3</sub>, C(O)C<sub>6</sub>H<sub>4</sub>-o-Br, C(O)C<sub>6</sub>H<sub>4</sub>-o-Cl, and C(O)C<sub>6</sub>H<sub>5</sub>;~~

iii) ~~when R<sub>1</sub> is Br and R<sub>2</sub> is H then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>H;~~

iv) ~~when R<sub>1</sub> is OH and R<sub>2</sub> is H then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>H;~~

v) when R<sub>1</sub> is H and R<sub>2</sub> is CH<sub>3</sub> then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not 2,6-dichloro-4-trifluoromethylphenoxy, C(O)NH-C<sub>6</sub>H<sub>4</sub>-p-OCH<sub>2</sub>CH<sub>3</sub>, NHC(O)CH(CH<sub>3</sub>)<sub>2</sub>, SCH<sub>3</sub>, C(O)-C<sub>6</sub>H<sub>4</sub>-p-O-C<sub>8</sub>H<sub>17</sub>, SCH<sub>2</sub>CH<sub>3</sub>, C(O)NHC<sub>6</sub>H<sub>5</sub>, CH(OCH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>OC(O)CH<sub>3</sub>, CO<sub>2</sub>H, CO<sub>2</sub>CH<sub>3</sub>, C(O)C<sub>6</sub>H<sub>4</sub>-p-NO<sub>2</sub>, C(O)C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub> and CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>;

vi) ~~when R<sub>1</sub> is OH and R<sub>2</sub> is CH<sub>3</sub> then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CH<sub>2</sub>OCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>OCH(CH<sub>3</sub>)<sub>2</sub> and CH<sub>2</sub>OH;~~

vii) ~~when R<sub>2</sub> is CH<sub>3</sub> then:~~

~~R<sub>1</sub> is not CH<sub>3</sub> and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not 2,6-dichloro-4-trifluoromethylphenoxy;~~

~~R<sub>1</sub> is not I and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>;~~

~~R<sub>1</sub> is not C(CH<sub>3</sub>)<sub>3</sub> and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not formyl;~~

~~R<sub>1</sub> is not Br and  $-[W]_n-X-[Y]_m-Z$  together is not  $CO_2CH_2CH_3$ ;~~

~~and~~

~~R<sub>1</sub> is not  $CH_2CH_2CH_2CH_3$  and  $-[W]_n-X-[Y]_m-Z$  together is not formyl;~~

viii) when R<sub>1</sub> is H and R<sub>2</sub> is  $CH_2CH_3$  then  $-[W]_n-X-[Y]_m-Z$  together is not  $CH_2SCH_2CH_3$ ,  $OCH_2CH_2CH=CH_2$ ,  $CH_2CH_2CH_2OH$ ,  $CH_2CH_2CHO$ ,  $CO_2CH_2CH_3$ ,  $OCH_3$ ,  $C(O)CH_2Br$ ,  $CO_2C_8H_{17}$ , formyl, OH,  $CH_2N(CH_2CH_2Cl)_2$ ,  $CH(CH_3)OC(O)CH_3$ ,  $CH_2OH$ ,  $CH_2OC(O)CH_3$ ,  $C(O)CH_3$ ,  $C(O)C_6H_5$  and  $C(O)NHCH_2CO_2CH_2CH_3$ .

ix) ~~when R<sub>1</sub> is  $CH_3$  and R<sub>2</sub> is  $CH_2CH_3$  then  $-[W]_n-X-[Y]_m-Z$  together is not  $CH(OH)C_6H_4-p-N(CH_3)_2$ ,  $C(O)CH_2C(O)CH_3$ ,  $CO_2CH_2C_6H_5$ ,  $CO_2CH_3$ ,  $C(O)CH_2CH_2CH_3$ ,  $C(O)CH_3$ ,  $C(O)C_6H_4-p-OCH_3$ ,  $C(O)C_6H_4-o-Br$ ,  $C(O)C_6H_4-p-Cl$ ,  $C(O)C_6H_4-o-Cl$ ,  $C(O)CH_2C_6H_5$  and  $C(O)C_6H_5$ ;~~

~~x) when R<sub>2</sub> is  $CH_2CH_3$  then:~~

~~R<sub>1</sub> is not I and  $-[W]_n-X-[Y]_m-Z$  together is not  $CO_2CH_2CH_3$ ;~~

~~R<sub>1</sub> is not  $CF_3$  and  $-[W]_n-X-[Y]_m-Z$  together is not  $CO_2CH_2CH_3$ ; and~~

~~R<sub>1</sub> is not Br and  $-[W]_n-X-[Y]_m-Z$  together is not  $CO_2CH_2CH_3$ ;~~

xi) ~~when R<sub>1</sub> is OH and R<sub>2</sub> is  $CH_2CH_3$  then  $-[W]_n-X-[Y]_m-Z$  together is not  $C(O)C_6H_5$ ,  $C(O)NH_2$  and  $CO_2CH_2CH_3$ ;~~

xii) ~~when R<sub>1</sub> is H and R<sub>2</sub> is  $C(CH_3)_3$  then  $-[W]_n-X-[Y]_m-Z$  together is not  $CO_2C(CH_3)_3$ ,  $C(O)NHC(O)CH_3$  and  $C(O)NH_2$ ;~~

xiii) ~~when R<sub>1</sub> is OH and R<sub>2</sub> is  $CH_2CH_2CH_2CH_3$  then  $-[W]_n-X-[Y]_m-Z$  together is not  $C(O)C_6H_5$ ; and~~

xiv) ~~when X is  $NR_3$  then "n" is 1.~~

Claims 2-151 are cancelled.

152. (Currently Amended) The compound according to claim 1 wherein W is the straight or branched C<sub>1-5</sub> alkylene group optionally containing one double bond[] or one triple bond ~~or carbonyl~~, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

153. (Currently Amended) The compound according to claim 1 ~~152~~ wherein W is selected from the group consisting of  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH(CH_3)CH_2-$ ,  $-CH_2CH(CH_3)-$ ,

~~-C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, and -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>C(O)-, C(O)CH<sub>2</sub>-,~~  
~~-CH(CH<sub>3</sub>)C(O)-, C(O)CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>C(O)-, C(O)CH<sub>2</sub>CH<sub>2</sub>-, C(CH<sub>3</sub>)<sub>2</sub>C(O)-, C(O)C(CH<sub>3</sub>)<sub>2</sub>-,~~  
~~-C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C(O)-, C(O)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, -CH<sub>2</sub>C(O)CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>C(O)-, C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-,~~  
~~-CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>C(O)-, C(O)CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>C(O)CH<sub>2</sub>-, -CH<sub>2</sub>C(O)CH<sub>2</sub>CH<sub>2</sub>-,~~  
~~CH=CHC(O)-, C(O)CH=CH-, C(CH<sub>3</sub>)=CHC(O)-, and C(O)CH=C(CH<sub>3</sub>)-,~~ each optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

154. (Currently Amended) The compound according to claim ~~1~~ ~~152~~ wherein W is -CH(CH<sub>3</sub>)-, -CH(OCH<sub>3</sub>)CH<sub>2</sub>-, or -CH<sub>2</sub>CH(OCH<sub>3</sub>)-, each optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

155. (Currently Amended) The compound according to claim ~~1~~ ~~152~~ wherein W is selected from the group consisting of -CH<sub>2</sub>-, -CH(CH<sub>3</sub>)-, -C(CH<sub>3</sub>)<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH(CH<sub>3</sub>)CH<sub>2</sub>-, -CH<sub>2</sub>CH(CH<sub>3</sub>)-, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, -CH(OCH<sub>3</sub>)CH<sub>2</sub>-, -CH<sub>2</sub>CH(OCH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, and -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, ~~-CH<sub>2</sub>C(O)-, C(O)CH<sub>2</sub>-, CH(CH<sub>3</sub>)C(O)-, C(O)CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>C(O)-, C(O)CH<sub>2</sub>CH<sub>2</sub>-, C(CH<sub>3</sub>)<sub>2</sub>C(O)-, C(O)C(CH<sub>3</sub>)<sub>2</sub>-, C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C(O)-, C(O)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, -CH<sub>2</sub>C(O)CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>C(O)-, C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>C(O)-, C(O)CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>C(O)CH<sub>2</sub>-, -CH<sub>2</sub>C(O)CH<sub>2</sub>CH<sub>2</sub>-, -CH=CHC(O)-, C(O)CH=CH-, C(CH<sub>3</sub>)=CHC(O)-, and -C(O)CH=C(CH<sub>3</sub>)-.~~

156. (Currently Amended) The compound according to claim ~~1~~ ~~152~~ wherein W is -CH=CH-[[,]] or -C≡C-, or -C(O)-.

157. (Previously Presented) The compound according to claim 1 wherein Y is the straight or branched chain C<sub>1-5</sub> alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

158. (Currently Amended) The compound according to claim ~~1~~ ~~157~~ wherein Y is selected from the group consisting of -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH(CH<sub>3</sub>)CH<sub>2</sub>-, -CH<sub>2</sub>CH(CH<sub>3</sub>)-, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -C≡CCH<sub>2</sub>-, -CH<sub>2</sub>C≡C-, -CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>-,

-CH(CH<sub>3</sub>)C(O)-, -C(O)CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>CH<sub>2</sub>-, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, -CH<sub>2</sub>C(O)CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>C(O)CH<sub>2</sub>-, -CH<sub>2</sub>C(O)CH<sub>2</sub>CH<sub>2</sub>-, -CH=CHC(O)-, -C(O)CH=CH-, -C(CH<sub>3</sub>)=CHC(O)-, and -C(O)CH=C(CH<sub>3</sub>)-, each optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

159. (Currently Amended) The compound according to claim 1 ~~157~~ wherein Y is selected from the group consisting of -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH(CH<sub>3</sub>)CH<sub>2</sub>-, -CH<sub>2</sub>CH(CH<sub>3</sub>)-, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -C≡CCH<sub>2</sub>-, -CH<sub>2</sub>C≡C-, -CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>-, -CH(CH<sub>3</sub>)C(O)-, -C(O)CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>CH<sub>2</sub>-, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, -CH<sub>2</sub>C(O)CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>C(O)CH<sub>2</sub>-, -CH<sub>2</sub>C(O)CH<sub>2</sub>CH<sub>2</sub>-, -CH=CHC(O)-, -C(O)CH=CH-, -C(CH<sub>3</sub>)=CHC(O)-, and -C(O)CH=C(CH<sub>3</sub>)-

160. (Currently Amended) The compound according to claim 1 ~~157~~ wherein Y is -CH(CH<sub>3</sub>)- optionally substituted with halogen, hydroxyl or C<sub>1-4</sub> alkoxy.

161. (Currently Amended) The compound according to claim 1 ~~157~~ wherein Y is -CH(OCH<sub>3</sub>)CH<sub>2</sub>- or -CH<sub>2</sub>CH(OCH<sub>3</sub>)- optionally substituted with halogen, hydroxyl or C<sub>1-4</sub> alkyl.

162. (Currently Amended) The compound according to claim 1 ~~157~~ wherein Y is -CH=CH- optionally substituted with C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

163. (Currently Amended) The compound according to claim ~~1~~ 157 wherein Y is  $-\text{C}(\text{CH}_3)_2-$ ,  $-\text{C}\equiv\text{C}-$ ,  $-\text{C}(\text{O})-$ ,  $-\text{C}(\text{CH}_3)_2\text{C}(\text{O})-$ , or  $-\text{C}(\text{O})\text{C}(\text{CH}_3)_2-$ .

164. (Previously Presented) The compound according to claim 1 wherein X is  $-\text{NHC}(\text{O})-$  or  $-\text{C}(\text{O})\text{NH}-$ .

165. (Previously Presented) The compound according to claim 1 wherein X is  $-\text{NH}-$  or  $-\text{NCH}_3-$ .

166. (Currently Amended) The compound according to claim 1 wherein X is selected from the group consisting of  ~~$-\text{C}(\text{O})-$~~ ,  $-\text{CH}(\text{OH})-$ ,  $-\text{C}(\text{NH})-$ ,  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ , or  $-\text{S}(\text{O})_2-$ .

167. (Previously Presented) The compound according to claim 1 wherein Z is H, halogen, or phenyl.

168. (Previously Presented) The compound according to claim 1 wherein Z is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of  $-\text{F}$ ,  $-\text{Cl}$ ,  $-\text{Br}$ ,  $-\text{CF}_3$ ,  $-\text{NHCH}_3$ ,  $-\text{N}(\text{CH}_3)_2$ ,  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{OCH}_3$  and  $-\text{OCF}_3$ .

169. (Previously Presented) The compound according to claim 1 wherein Z is heteroaryl optionally substituted with 1 to 3 substituents selected from the group consisting of  $-\text{F}$ ,  $-\text{Cl}$ ,  $-\text{Br}$ ,  $-\text{CF}_3$ ,  $-\text{NHCH}_3$ ,  $-\text{N}(\text{CH}_3)_2$ ,  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{OCH}_3$  and  $-\text{OCF}_3$ .

170. (Previously Presented) The compound according to claim 1 wherein  $\text{R}_1$  is H.

171. (Cancelled)

172. (Previously Presented) The compound according to claim 1 wherein  $\text{R}_1$  is halogen.

173. (Previously Presented) The compound according to claim 1 wherein  $\text{R}_1$  is  $\text{C}_{1-4}$  alkyl.

174. (Previously Presented) The compound according to claim 1 wherein  $\text{R}_1$  is  $\text{C}_{1-4}$  haloalkyl.


175. (Previously Presented) The compound according to claim 1 wherein R<sub>2</sub> is H.
176. (Previously Presented) The compound according to claim 1 wherein R<sub>2</sub> is C<sub>1-8</sub> alkyl.
177. (Currently Amended) The according to claim 1 selected from the group consisting of:
- 5-Ethylsulfanylmethyl-1H-pyrazole-3-carboxylic acid;
  - 5-Ethanesulfinylmethyl-1H-pyrazole-3-carboxylic acid;
  - 5-Ethanesulfonylmethyl-1H-pyrazole-3-carboxylic acid;
  - 5-(2-Oxo-propoxymethyl)-1H-pyrazole-3-carboxylic acid;
  - 5-Prop-2-ynyloxymethyl-1H-pyrazole-3-carboxylic acid;
  - ~~5-Carbameoyl-1H-pyrazole-3-carboxylic acid;~~
  - 5-(1-Methylsulfanyl-ethyl)-1H-pyrazole-3-carboxylic acid;
  - 5-(1-Methanesulfinyl-ethyl)-1H-pyrazole-3-carboxylic acid;
  - 5-(1-Methanesulfonyl-ethyl)-1H-pyrazole-3-carboxylic acid;
  - 5-(1,1-Dimethoxy-ethyl)-1H-pyrazole-3-carboxylic acid;
  - ~~5-(2-Carboxy-1,1-dimethyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~
  - 5-(1-Acetoxy-ethyl)-1H-pyrazole-3-carboxylic acid;
  - ~~5-(3-Hydroxy-propyl)-1H-pyrazole-3-carboxylic acid;~~
  - ~~5-(1-Chloro-3-hydroxy-propyl)-1H-pyrazole-3-carboxylic acid;~~
  - ~~5-(2-Hydroxy-ethyl)-1H-pyrazole-3-carboxylic acid;~~
  - ~~5-(2-Hydroxy-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~
  - ~~5-(2-Carboxy-1-methyl-vinyl)-1H-pyrazole-3-carboxylic acid;~~
  - 5-Propylcarbamoylmethyl-1H-pyrazole-3-carboxylic acid;
  - ~~5-(2-Amino-vinyl)-1H-pyrazole-3-carboxylic acid;~~
  - ~~5-(2-Amino-propyl)-1H-pyrazole-3-carboxylic acid;~~
  - 5-(2-Dimethylamino-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;
  - ~~5-(1-Hydroxy-ethyl)-1H-pyrazole-3-carboxylic acid;~~
  - ~~5-(1-Hydroxy-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~
  - ~~5-(2-Hydroxy-2-methyl-propyl)-1H-pyrazole-3-carboxylic acid;~~
  - ~~5-(3-Carboxy-1-methyl-propyl)-1H-pyrazole-3-carboxylic acid;~~
  - ~~5-(2-Carboxy-vinyl)-1H-pyrazole-3-carboxylic acid;~~

5-(2-Methoxy-vinyl)-1H-pyrazole-3-carboxylic acid;  
5-(3-Acetoxy-propyl)-1H-pyrazole-3-carboxylic acid;  
~~5-Carbamoylmethyl-1H-pyrazole-3-carboxylic acid;~~  
~~5-Hydroxymethyl-1H-pyrazole-3-carboxylic acid;~~  
5-(2,2-Dimethoxy-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(2-Imino-propyl)-1H-pyrazole-3-carboxylic acid;  
~~5-(2-Amino-2-methyl-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(Ethoxycarbonyl-fluoro-methyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Ethoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-Ethoxycarbonylmethyl-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Ethoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
5-Methoxymethyl-1H-pyrazole-3-carboxylic acid;  
~~5-(1-Methoxycarbonyl-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Hydroxy-1-methoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(3-Methoxycarbonyl-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Methoxycarbonyl-vinyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-Dimethylearbamoylmethyl-1H-pyrazole-3-carboxylic acid;~~  
1H-Pyrazole-3,5-dicarboxylic acid;  
5-Ethoxymethyl-1H-pyrazole-3-carboxylic acid;  
5-(2-Methoxy-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(3-Methoxy-propyl)-1H-pyrazole-3-carboxylic acid;  
5-Methylsulfanylmethyl-1H-pyrazole-3-carboxylic acid;  
5-Methanesulfinylmethyl-1H-pyrazole-3-carboxylic acid;  
5-Methanesulfonylmethyl-1H-pyrazole-3-carboxylic acid;  
5-(2-Methylsulfanyl-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(2-Methanesulfinyl-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(2-Methanesulfonyl-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(3-Methylsulfanyl-propyl)-1H-pyrazole-3-carboxylic acid;  
5-(3-Methanesulfinyl-propyl)-1H-pyrazole-3-carboxylic acid;  
5-(3-Methanesulfonyl-propyl)-1H-pyrazole-3-carboxylic acid;  
~~5-(2-Amino-ethyl)-1H-pyrazole-3-carboxylic acid;~~



5-(2-Methylamino-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(2-Dimethylamino-ethyl)-1H-pyrazole-3-carboxylic acid;  
~~5-(2-Oxo-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(3-Oxo-butyl)-1H-pyrazole-3-carboxylic acid;~~  
5-(Benzylamino-methyl)-1H-pyrazole-3-carboxylic acid;  
5-Methoxymethyl-1H-pyrazole-3-carboxylic acid;  
5-Ethoxymethyl-1H-pyrazole-3-carboxylic acid; or  
5-(2,2-Diethoxy-ethyl)-1H-pyrazole-3-carboxylic acid; or  
a pharmaceutically acceptable salt, solvate or hydrate thereof.

178. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with at least one compound according to Formula (I):



wherein:

~~W and Y are independently~~ is a straight or branched chain C<sub>1-5</sub> alkylene group optionally containing one double bond ~~[[,]]~~ or one triple bond ~~or carbonyl~~, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or C<sub>1-4</sub> alkoxy;

Y is a straight or branched chain C<sub>1-5</sub> alkylene group optionally containing one double bond, or one triple bond or carbonyl, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or C<sub>1-4</sub> alkoxy;

X is -NR<sub>3</sub>C(O)-, -C(O)NR<sub>3</sub>, -NR<sub>3</sub>S(O)<sub>2</sub>-, -S(O)<sub>2</sub>NR<sub>3</sub>-,  
-NR<sub>3</sub>C(O)NR<sub>4</sub>-, -NR<sub>3</sub>C(O)O-, -OC(O)NR<sub>3</sub>-, -NR<sub>3</sub>-, ~~-C(O)-~~, -CH(OH)-, -C(NH)-, -O-, -S-, -S(O)- or -S(O)<sub>2</sub>-;

R<sub>3</sub> and R<sub>4</sub> are independently H, C<sub>1-4</sub> alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C<sub>1-4</sub>

haloalkyl, amino, C<sub>1-4</sub> alkylamino, di-C<sub>1-4</sub>-alkylamino, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> haloalkylthio, C<sub>1-4</sub> haloalkylsulfinyl and C<sub>1-4</sub> haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C<sub>1-4</sub> haloalkyl, amino, C<sub>1-4</sub> alkylamino, di-C<sub>1-4</sub>-alkylamino, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> haloalkylthio, C<sub>1-4</sub> haloalkylsulfinyl and C<sub>1-4</sub> haloalkylsulfonyl;

R<sub>1</sub> is H, ~~hydroxyl~~, halogen, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl;

R<sub>2</sub> is H or C<sub>1-8</sub> alkyl and

"n" and "m" are each ~~independently 0 or 1~~; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

~~provided that when X is NR<sub>3</sub>, then "n" is 1.~~

179. (Previously Presented) A method for prophylaxis or treatment of a metabolic-related disorder in an individual in need of said prophylaxis or treatment comprising administering to the individual a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 178.
180. (Previously Presented) The method according to claim 179 wherein the metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.
181. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
182. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is dyslipidemia.

183. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is atherosclerosis.
184. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is coronary heart disease.
185. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is insulin resistance.
186. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is type 2 diabetes.
187. (Previously Presented) The method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.